Lynx1 Capital Management LP Invests $2.92 Million in Precision BioSciences, Inc. (NASDAQ:DTIL)

Lynx1 Capital Management LP acquired a new position in shares of Precision BioSciences, Inc. (NASDAQ:DTIL - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 766,051 shares of the company's stock, valued at approximately $2,919,000. Precision BioSciences comprises 1.1% of Lynx1 Capital Management LP's portfolio, making the stock its 12th largest holding. Lynx1 Capital Management LP owned 9.99% of Precision BioSciences at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in DTIL. Moloney Securities Asset Management LLC boosted its stake in shares of Precision BioSciences by 177.0% in the fourth quarter. Moloney Securities Asset Management LLC now owns 87,799 shares of the company's stock valued at $335,000 after buying an additional 56,100 shares during the period. Dimensional Fund Advisors LP bought a new stake in shares of Precision BioSciences during the 4th quarter valued at $211,000. Renaissance Technologies LLC grew its holdings in shares of Precision BioSciences by 36.2% during the 4th quarter. Renaissance Technologies LLC now owns 109,798 shares of the company's stock worth $418,000 after purchasing an additional 29,200 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Precision BioSciences by 40.7% in the third quarter. Geode Capital Management LLC now owns 65,974 shares of the company's stock worth $591,000 after purchasing an additional 19,088 shares during the period. Finally, XTX Topco Ltd acquired a new position in Precision BioSciences in the fourth quarter valued at about $67,000. Institutional investors own 37.99% of the company's stock.

Precision BioSciences Price Performance

Precision BioSciences stock traded up $0.08 during midday trading on Thursday, reaching $5.72. The company's stock had a trading volume of 124,716 shares, compared to its average volume of 181,195. The stock has a market cap of $60.35 million, a PE ratio of 95.35 and a beta of 1.59. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.34. The business has a 50-day moving average price of $5.03 and a 200-day moving average price of $5.78. Precision BioSciences, Inc. has a 52 week low of $3.61 and a 52 week high of $13.44.

Precision BioSciences (NASDAQ:DTIL - Get Free Report) last issued its quarterly earnings results on Wednesday, March 26th. The company reported ($3.20) EPS for the quarter, missing analysts' consensus estimates of ($2.09) by ($1.11). Precision BioSciences had a negative return on equity of 23.69% and a net margin of 11.48%. The business had revenue of $3.47 million for the quarter, compared to analyst estimates of $4.28 million. On average, sell-side analysts predict that Precision BioSciences, Inc. will post -1.23 EPS for the current year.

Wall Street Analyst Weigh In

DTIL has been the subject of several analyst reports. HC Wainwright restated a "buy" rating and issued a $60.00 target price on shares of Precision BioSciences in a research report on Friday, March 28th. BMO Capital Markets upgraded shares of Precision BioSciences from a "market perform" rating to an "outperform" rating and set a $34.00 price objective for the company in a research report on Friday, January 10th.

Precision BioSciences Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.